Safety of Microporous Annealed Particle (MAP) Wound Matrix in Patients with Clean Surgical Wounds.

Eligibility Criteria

• * Willing to undergo the written informed consent process prior to enrollment in this study.
• * At least 22 years of age at screening.
• * Has non-melanoma skin cancer and be scheduled for skin cancer surgery with Mohs micrographic surgery on a location suitable for secondary intention healing.
• * Resulting surgical wound after Mohs micrographic surgery must be at least 1 cm and no more than 4 cm in diameter (or surface area of at least 0.8 cm2 and no more than 12.6 cm2).
• * Resulting surgical wound after Mohs micrographic surgery must be full thickness.
• * Willing to return for all required follow-up visits.
• * Willing to follow the instructions of the Principal Investigator.
• * Has uncontrolled Type I or Type II diabetes and HbA1c values greater than 8.0% within the last 6 months.
• * Has a known infection in the area of the Mohs micrographic surgery.
• * Has a known allergy to any of the components of the TT101 Device.
• * Is an active daily cigarette smoker.
• * Is pregnant or lactating.
• * Is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or surgical sterilization of partner).
• * Has clinical evidence of Peripheral Vascular Disease (PVD) in the form of grade 2 pitting Edema or higher.
• * Has been diagnosed with a surgical or wound site infection within the last 6-months.
• * Has been diagnosed with chronic ulcer or wound within the last 12- months.
• * Has a remote active infection concurrent with having the Mohs micrographic surgery.
• * Per Investigator's discretion the subject is not appropriate for inclusion in the trial.